Fvasconcellos [Public domain] via Wikimedia Commons
About 20% of breast cancers have elevated levels of the protein HER2. Treatment with drugs that target HER2, such as a combination of trastuzumab and lapatinib, can lead to improved outcomes in such cases, but many tumors eventually become resistant to this therapy. Joan T. Garrett (Vanderbilt University Medical Center, Nashville, TN) studied the development of resistance in HER2-positive breast cancer with the goal of identifying better treatment strategies for these tumors.
Lab Anim. (NY) 43, 181 (2014).
view full text (login required)